Ganapathy Krishnan1, Karl D'Silva, Anas Al-Janadi. Show Affiliations » 1. Department of Internal Medicine, Division of Hematology and Oncology, Michigan State University, East Lansing, MI, USA.
Abstract
Entities: Chemical Disease
Mesh: See more » Adenocarcinoma/drug therapyAdenocarcinoma/secondaryAntibodies, Monoclonal/adverse effectsAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedAntineoplastic Agents/adverse effectsAntineoplastic Agents/therapeutic useCetuximabColonic Neoplasms/drug therapyColonic Neoplasms/pathologyHumansLiver Neoplasms/drug therapyLiver Neoplasms/secondaryMaleMiddle AgedTumor Lysis Syndrome/etiology
Substances: See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCetuximab
Year: 2008 PMID: 18467734 DOI: 10.1200/JCO.2007.14.7603
Source DB: PubMed Journal: J Clin Oncol ISSN: 0732-183X Impact factor: 44.544